Bionic Sight
Phase 2Bionic Sight: a new treatment for advanced stage blindness combining gene therapy with a neural coding device
Founded
2017
Focus
RNA & Gene Therapy
About
Bionic Sight: a new treatment for advanced stage blindness combining gene therapy with a neural coding device
Pipeline Snapshot
22 drugs in pipeline
| Drug | Indication | Stage |
|---|---|---|
| BS01 | Retinitis Pigmentosa | Phase 1/2 |
| BS01 | Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD) | Phase 1/2 |
Funding History
5Total raised: $21.5M
Series A$6.2MGray Matters CapitalMar 15, 2022
Series A$12MUndisclosedOct 15, 2020
Seed$1.8MUndisclosedMay 15, 2020
Grant$300KNational Institutes of Health (NIH)Jun 15, 2019
Company Info
TypePrivate
Founded2017
LocationNew York, United States
StagePhase 2
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile